{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:19:46Z","timestamp":1783603186173,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["IP-2016-06-8046"],"award-info":[{"award-number":["IP-2016-06-8046"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["IP-2016-06-8046"],"award-info":[{"award-number":["IP-2016-06-8046"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41409-026-02903-3","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:04:07Z","timestamp":1779210247000},"page":"883-890","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Von Willebrand factor and factor VIII as potential biomarkers for diagnosis and disease monitoring in chronic graft-versus-host disease"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8564-9544","authenticated-orcid":false,"given":"Antonela","family":"Lelas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Desnica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Sabol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8327-9913","authenticated-orcid":false,"given":"Desiree Coen","family":"Herak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Milos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9186-2586","authenticated-orcid":false,"given":"Ana Zelic","family":"Kerep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ante","family":"Vulic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5842-0911","authenticated-orcid":false,"given":"Nadira","family":"Durakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranka","family":"Serventi-Seiwerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3323-3487","authenticated-orcid":false,"given":"Radovan","family":"Vrhovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9111-9354","authenticated-orcid":false,"given":"Steven Z.","family":"Pavletic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3755-4477","authenticated-orcid":false,"given":"Drazen","family":"Pulanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"2903_CR1","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/s41409-025-02697-w","volume":"60","author":"D Pulanic","year":"2025","unstructured":"Pulanic D, Peczynski C, Boreland W, Rautenberg C, Kr\u00f6ger N, Michonneau D, et al. Chronic graft-versus-host disease trends over 30 years: a study by the EBMT transplant complications working party. Bone Marrow Transpl. 2025;60:1436\u201344.","journal-title":"Bone Marrow Transpl"},{"key":"2903_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/frtra.2024.1332181","volume":"3","author":"R Langer","year":"2024","unstructured":"Langer R, Lelas A, Rittenschober M, Piekarska A, Sadowska-Klasa A, Sabol I, et al. Retrospective analysis of the incidence and outcome of late acute and chronic graft-versus-host disease\u2014an analysis from transplant centers across Europe. Front Transpl. 2024;3:1332181.","journal-title":"Front Transpl"},{"key":"2903_CR3","first-page":"448","volume":"27","author":"SZ Pavletic","year":"2021","unstructured":"Pavletic SZ, Martin PJ, Schultz KR, Lee SJ. The future of chronic Graft-versus-Host Disease: introduction to the 2020 National Institutes of Health Consensus Development Project reports. Transpl Cell Ther. 2021;27:448\u201351.","journal-title":"Transpl Cell Ther"},{"key":"2903_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","volume":"23","author":"KR Cooke","year":"2017","unstructured":"Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, et al. The biology of chronic Graft-versus-Host Disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transpl. 2017;23:211\u201334.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2903_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.676756","volume":"12","author":"A Lelas","year":"2021","unstructured":"Lelas A, Greinix HT, Wolff D, Eissner G, Pavletic SZ, Pulanic D. Von Willebrand factor, factor VIII, and other acute-phase reactants as biomarkers of inflammation and endothelial dysfunction in chronic Graft-versus-Host Disease. Front Immunol. 2021;12:676756.","journal-title":"Front Immunol"},{"key":"2903_CR6","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1161\/ATVBAHA.116.308225","volume":"36","author":"MAH Sonneveld","year":"2016","unstructured":"Sonneveld MAH, Franco OH, Ikram MA, Hofman A, Kavousi M, De Maat MPM, et al. Von Willebrand factor, ADAMTS13, and the risk of mortality: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2016;36:2446\u201351.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2903_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1365-2141.1999.01317.x","volume":"105","author":"A Rumley","year":"1999","unstructured":"Rumley A, Lowe GD, Sweetnam PM, Yarnell JWG, Ford RP. Factor VIII, von Willebrand factor, and the risk of major ischemic heart disease in the Caerphilly Heart Study. Br J Haematol. 1999;105:110\u20136.","journal-title":"Br J Haematol"},{"key":"2903_CR8","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1161\/CIRCULATIONAHA.108.792986","volume":"118","author":"DS Frankel","year":"2008","unstructured":"Frankel DS, Meigs JB, Massaro JM, Wilson PWF, O\u2019Donnell CJ, D\u2019Agostino RB, et al. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the Framingham Offspring Study. Circulation. 2008;118:2533\u20139.","journal-title":"Circulation"},{"key":"2903_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/rheumatology\/29.1.6","volume":"29","author":"JP James","year":"1990","unstructured":"James JP, Stevens TRJ, Hall ND, Maddison PJ, Goulding NJ, Silman A, et al. Factor VIII related antigen in connective tissue disease patients and relatives. Rheumatology. 1990;29:6\u20139.","journal-title":"Rheumatology"},{"key":"2903_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/ar295","volume":"3","author":"A Scheja","year":"2001","unstructured":"Scheja A, \u00c5kesson A, Geborek P, Wildt M, Wollheim CB, Wollheim FA, et al. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). Arthritis Res. 2001;3:178\u201382.","journal-title":"Arthritis Res"},{"key":"2903_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2016-000162","volume":"3","author":"JC Nossent","year":"2016","unstructured":"Nossent JC, Raymond WD, Eilertsen G\u00d8. Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation. Lupus Sci Med. 2016;3:e000175.","journal-title":"Lupus Sci Med"},{"key":"2903_CR12","first-page":"320","volume":"50","author":"AD Blann","year":"1991","unstructured":"Blann AD. Von Willebrand factor antigen as an acute-phase reactant and marker of endothelial cell injury in connective tissue diseases: a comparison with CRP, rheumatoid factor, and erythrocyte sedimentation rate. Z Rheumatol. 1991;50:320\u201332.","journal-title":"Z Rheumatol"},{"key":"2903_CR13","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1093\/rheumatology\/kes068","volume":"51","author":"T Barnes","year":"2012","unstructured":"Barnes T, Gliddon A, Dor\u00e9 CJ, Maddison P, Moots RJ. Baseline vWF factor predicts the development of elevated pulmonary artery pressure in systemic sclerosis. Rheumatology. 2012;51:1606\u20139.","journal-title":"Rheumatology"},{"key":"2903_CR14","first-page":"103","volume":"26","author":"D D\u2019Cruz","year":"1999","unstructured":"D\u2019Cruz D, Direskeneli H, Khamashta M, Hughes GRV. Lymphocyte activation markers and von Willebrand factor antigen in Wegener\u2019s granulomatosis: potential markers for disease activity. J Rheumatol. 1999;26:103\u20139.","journal-title":"J Rheumatol"},{"key":"2903_CR15","doi-asserted-by":"publisher","first-page":"SI228","DOI":"10.1093\/rheumatology\/kead600","volume":"63","author":"E Go","year":"2024","unstructured":"Go E, Aeschlimann FA, Lu H, Larry JR, Hebert D, Yeung RSM, et al. Von Willebrand factor antigen as a marker of disease activity in childhood-onset antineutrophil cytoplasmic antibody\u2013associated vasculitis. Rheumatol (Oxf). 2024;63:SI228\u2013SI232.","journal-title":"Rheumatol (Oxf)"},{"key":"2903_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/rheumatology\/30.6.433","volume":"30","author":"CS Lau","year":"1991","unstructured":"Lau CS, Mclaren M, Belch JJF. Factor VIII von Willebrand factor antigen levels correlate with symptom severity in patients with Raynaud\u2019s phenomenon. Br J Rheumatol. 1991;30:433\u20136.","journal-title":"Br J Rheumatol"},{"key":"2903_CR17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/0140-6736(90)90736-O","volume":"335","author":"PE Rose","year":"1990","unstructured":"Rose PE, Kavi J, Chant I, Taylor CM, Struthers GS, Robertson M. Factor VIII von Willebrand protein in haemolytic uraemic syndrome and systemic vasculitides. Lancet. 1990;335:500\u20132.","journal-title":"Lancet"},{"key":"2903_CR18","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.18295\/2075-0528.1571","volume":"14","author":"JK Alkaabi","year":"2014","unstructured":"Alkaabi JK, Gravell D, Al-Haddabi H, Pathare A. Haemostatic parameters in patients with Beh\u00e7et\u2019s disease. Sultan Qaboos Univ Med J. 2014;14:e190\u20136.","journal-title":"Sultan Qaboos Univ Med J"},{"key":"2903_CR19","first-page":"1343","volume":"100","author":"BC Biedermann","year":"2002","unstructured":"Biedermann BC, Tsakiris DA, Gregor M, Jeanneret C, Pober JS, Gratwohl A, et al. Endothelial injury mediated by cytotoxic T lymphocytes and exposure to lipopolysaccharide: the role of tumor necrosis factor alpha. Blood. 2002;100:1343\u20139.","journal-title":"Blood"},{"key":"2903_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/MBC.0b013e32834cb35d","volume":"23","author":"MI Hassan","year":"2012","unstructured":"Hassan MI, Saxena A, Ahmad F. Structure and function of von Willebrand factor: the protein that is deficient and\/or abnormal in inherited von Willebrand disease. Blood Coagul Fibrinolysis. 2012;23:11\u201322.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2903_CR21","first-page":"1471","volume":"139","author":"J Gebrane-Youn\u00e8s","year":"1991","unstructured":"Gebrane-Youn\u00e8s J, Drouet L, Caen JP, Orcel L. Heterogeneous distribution of Weibel-Palade bodies and von Willebrand factor along the porcine vascular tree. Am J Pathol. 1991;139:1471\u20139.","journal-title":"Am J Pathol"},{"key":"2903_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1369\/jhc.4A6514.2005","volume":"54","author":"MP Pusztaszeri","year":"2006","unstructured":"Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem. 2006;54:385\u201395.","journal-title":"J Histochem Cytochem"},{"key":"2903_CR23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3324\/haematol.2015.129858","volume":"100","author":"VR Arruda","year":"2015","unstructured":"Arruda VR. The search for the origin of factor VIII synthesis and its impact on therapeutic strategies for hemophilia A. Haematologica. 2015;100:849\u201350.","journal-title":"Haematologica"},{"key":"2903_CR24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transpl. 2005;11:945\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2903_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/leu.2011.254","volume":"26","author":"L Grkovic","year":"2012","unstructured":"Grkovic L, Baird K, Steinberg SM, Williams KM, Pulanic D, Cowen EW, et al. Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity. Leukemia. 2012;26:633\u201343.","journal-title":"Leukemia"},{"key":"2903_CR26","doi-asserted-by":"publisher","first-page":"e007635","DOI":"10.1136\/jitc-2023-007635","volume":"12","author":"O Penack","year":"2024","unstructured":"Penack O, Luft T, Peczynski C, Benner A, Sica S, Arat M, et al. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study. J Immunother Cancer. 2024;12:e007635.","journal-title":"J Immunother Cancer"},{"key":"2903_CR27","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1111\/jth.14304","volume":"16","author":"LL Swystun","year":"2018","unstructured":"Swystun LL, Lillicrap D. Genetic regulation of plasma von Willebrand factor levels in health and disease. J Thromb Haemost. 2018;16:2375\u201390.","journal-title":"J Thromb Haemost"},{"key":"2903_CR28","doi-asserted-by":"crossref","unstructured":"Song J, Chen F, Campos M, Bolgiano D, Houck K, Chambless LE, et al. Quantitative influence of ABO blood groups on factor VIII and its ratio to von Willebrand factor, novel observations from an ARIC study of 11,673 Subjects. PLoS One. 2015;10:e0132626.","DOI":"10.1371\/journal.pone.0132626"},{"key":"2903_CR29","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1111\/j.1538-7836.2010.04034.x","volume":"8","author":"B van Zaane","year":"2010","unstructured":"van Zaane B, Nur E, Squizzato A, Gerdes VE, B\u00fcller HR, Dekkers OM, et al. Systematic review on the effect of glucocorticoid use on procoagulant, anticoagulant and fibrinolytic factors. J Thromb Haemost. 2010;8:2483\u201393.","journal-title":"J Thromb Haemost"},{"key":"2903_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3324\/haematol.2018.198275","volume":"104","author":"EM Staley","year":"2019","unstructured":"Staley EM, Cao W, Pham HP, Kim CH, Kocher NK, Zheng L, et al. Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura. Haematologica. 2019;104:166.","journal-title":"Haematologica"},{"key":"2903_CR31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1055\/s-0038-1649589","volume":"70","author":"MG Conlan","year":"1993","unstructured":"Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G. at al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1993;70:380\u20135.","journal-title":"Thromb Haemost"},{"key":"2903_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389\u2013401.e1.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2903_CR33","first-page":"747.e1","volume":"28","author":"AH Yang","year":"2022","unstructured":"Yang AH, Han MAT, Samala N, Rizvi BS, Marchalik R, Etzion O, et al. Characterization of hepatic dysfunction in subjects diagnosed with chronic GVHD by NIH consensus criteria. Transpl Cell Ther. 2022;28:747.e1\u2013747.e10.","journal-title":"Transpl Cell Ther"},{"key":"2903_CR34","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1182\/blood.2023019799","volume":"142","author":"K Umino","year":"2023","unstructured":"Umino K, Morita K, Ikeda T, Kawaguchi SI, Nagayama T, Ito S, et al. Antibody-mediated pathogenesis of chronic GVHD through DBY\/HLA class II complexes and induction of a GVL effect. Blood. 2023;142:1008\u201321.","journal-title":"Blood"},{"key":"2903_CR35","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood.2023021357","volume":"142","author":"NG Holtzman","year":"2023","unstructured":"Holtzman NG, Pavletic SZ. W\u201cH-Y\u201d antigen\/HLA complexes in chronic GVHD. Blood. 2023;142:946\u20138.","journal-title":"Blood"},{"key":"2903_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nm0302-233","volume":"8","author":"D Kreisel","year":"2002","unstructured":"Kreisel D, Krupnick AS, Gelman AE, Engels FH, Popma SH, Krasinskas AM, et al. Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat Med. 2002;8:233\u20139.","journal-title":"Nat Med"},{"key":"2903_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/intimm\/dxr041","volume":"23","author":"G Eissner","year":"2011","unstructured":"Eissner G, Hartmann I, Kesikli A, Holler E, Haffner S, Sax T, et al. CD4+CD25+FoxP3+ regulatory T cells enhance the allogeneic activity of endothelial-specific CD8+\/CD28-CTL. Int Immunol. 2011;23:485\u201392.","journal-title":"Int Immunol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02903-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02903-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02903-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:59:14Z","timestamp":1783601954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02903-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2903"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02903-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the institutional ethics committees of both UHC Zagreb and the University of Zagreb School of Medicine, and written informed consent was obtained from all participants. All methods were conducted in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}